On the eve of the world day of struggle with multiple sclerosis, which is celebrated on may 27, in Russia launched a nationwide project #Iewpoint aimed at raising awareness about multiple sclerosis (MS). Russia is home to about 100 thousand patients suffering from this disease. This figure is called the Head of the Duma Committee on health Dmitry Morozov, speaking at a press conference dedicated to this disease.
“Sickness took them at a young age with different clinical variants of the disease, requiring different approaches to treatment, but the clinical guidelines which currently operate, do not allow us to treat and rehabilitate these patients as we would like, so they need to be rethought taking into account new drugs” — said the MP.
At the same time, there are significant achievements in helping such patients: the government has included multiple sclerosis in the program of “14 high-cost nosologies” created registers of patients allocated funding. However, the problem of drug supply to the end not removed: the main part of appeals to the authorities lies in this plane is also the problem of interchangeability of LP, rehabilitation that requires regulation.
President of all-Russian public organization of disabled patients with multiple sclerosis Yan Vlasov, the situation with drugs from multiple sclerosis evaluates very positively. “Any innovative product from multiple sclerosis, which is registered on the planet, in the course of the year is coming to Russia, — the public man noted. — 1-2 year in Russia it comes in any of the lists, and is free of charge to our patients, and the cost can be from 200 thousand to 1.5 million rubles.”
Multiple sclerosis to date is an incurable disease, but the available pharmacotherapy is able to significantly improve the quality of life of these patients, allows to slow down his flow and push back disability for 15-20 years, these people have the opportunity to live a full life, to raise children, to work. According to Vlasov, in Europe, life expectancy with MS not less than the average for the population.
In the treatment of multiple sclerosis used drugs that suppress autoimmune inflammation — selective immunomodulators and immunosuppressants. Currently in the world approved 15 drugs for the treatment of multiple sclerosis in the future – the annual appearance of new drugs with proven efficacy, said Professor of the Department of neurology of the First Saint Petersburg state medical University of I. P. Pavlov feature Natalia totolyan. “The speed of introduction of new drugs in Russia is good, lags behind the EU countries and the USA for about 2-3 years, she said. But there’s a plus. While we have addressed the issue of inclusion of the drug in the preferential list, other countries have faced long-term complications from this drug. And we have not only the drug but also recommendations on how to avoid these complications.”
CEO of Merck in Russia and the CIS countries Matthias Wernicke noticed that in his company work to ensure that in the next 10 years the world has a drug that can completely cure this disease.
Multiple sclerosis is a chronic autoimmune disease that affects the myelin sheath of nerve fibers in the brain and spinal cord. The disease is usually diagnosed from age 20 to 40 years and is accompanied by various neurological disorders.
According to the results of a study presented by the sociological company “Levada-center” in cooperation with pharmaceutical company Roche in April last year, every second patient with progressive multiple sclerosis does not receive effective therapy.
So, interviewing 540 people across the Internet, pollsters found that 56% of respondents are not satisfied with the amount of information available about the disease, 36% of patients experiencing a delay in receiving medicines people with relapsing multiple sclerosis are more likely to appreciate ongoing therapy as effective (41%), while more than half of patients with progressive MS often are not satisfied with the treatment. The quality and standard of living generally satisfied with 52% of respondents.